Investigational Drug Information for GTS-21
✉ Email this page to a colleague
What is the development status for investigational drug GTS-21?
GTS-21 is an investigational drug.
There have been 10 clinical trials for GTS-21.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2022.
The most common disease conditions in clinical trials are Schizophrenia, Tourette Syndrome, and Syndrome. The leading clinical trial sponsors are VA Office of Research and Development, University of Colorado, Denver, and CoMentis.
There are twenty-three US patents protecting this investigational drug and two hundred and fifty-two international patents.
Summary for GTS-21
| US Patents | 23 |
| International Patents | 252 |
| US Patent Applications | 134 |
| WIPO Patent Applications | 57 |
| Japanese Patent Applications | 31 |
| Clinical Trial Progress | Phase 2 (2022-01-01) |
| Vendors | 32 |
Recent Clinical Trials for GTS-21
| Title | Sponsor | Phase |
|---|---|---|
| Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA) | UNITAID | Phase 3 |
| Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA) | Barcelona Institute for Global Health | Phase 3 |
| Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions | National Institute on Drug Abuse (NIDA) | Phase 2 |
Clinical Trial Summary for GTS-21
Top disease conditions for GTS-21
Top clinical trial sponsors for GTS-21
US Patents for GTS-21
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GTS-21 | ⤷ Try a Trial | Combination compositions and their use in methods for treating obesity and obesity-related disorders | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | ⤷ Try a Trial |
| GTS-21 | ⤷ Try a Trial | Methods and compositions for treatment of central nervous system disorders | Targacept, Inc. (Winston-Salem, NC) Medical College of Georgia Research Institute, Inc. (Augusta, GA) | ⤷ Try a Trial |
| GTS-21 | ⤷ Try a Trial | Amide derivatives as positive allosteric modulators and methods of use thereof | Abbott Laboratories (Abbott Park, IL) | ⤷ Try a Trial |
| GTS-21 | ⤷ Try a Trial | Alpha 7 nicotinic receptor selective ligands | University of Florida Research Foundation (Gainesville, FL) | ⤷ Try a Trial |
| GTS-21 | ⤷ Try a Trial | 1,2,4 oxadiazole compounds and methods of use thereof | AbbVie Inc. (North Chicago, IL) | ⤷ Try a Trial |
| GTS-21 | ⤷ Try a Trial | Alpha7 nicotinic receptor selective ligands | University of Florida Research Foundation, Inc. (Gainesville, FL) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GTS-21
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GTS-21 | European Patent Office | EP3297676 | 2035-05-22 | ⤷ Try a Trial |
| GTS-21 | World Intellectual Property Organization (WIPO) | WO2016188932 | 2035-05-22 | ⤷ Try a Trial |
| GTS-21 | Australia | AU2002362115 | 2021-12-31 | ⤷ Try a Trial |
| GTS-21 | World Intellectual Property Organization (WIPO) | WO03057140 | 2021-12-31 | ⤷ Try a Trial |
| GTS-21 | Australia | AU1088299 | 2017-10-23 | ⤷ Try a Trial |
| GTS-21 | Australia | AU752331 | 2017-10-23 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
